BOSTON, MA (May 15, 2025) –
The Davis Companies secured a full-building lease agreement at 100 Technology Way in Smithfield, RI, an approximately 123,000-square-foot biomanufacturing facility, with Organogenesis Holdings Inc., a leading regenerative medicine company. Lease terms were not disclosed.
“In a competitive manufacturing and life sciences market, our lease agreement with Organogenesis demonstrates Davis’ commitment to providing premier tenant experiences in locations that best allow businesses to innovate and scale,” said Davis SVP of asset management Jon Needham. “We are thrilled to welcome Organogenesis to the building and to support their growth plans as the company leads in the biomanufacturing sector and enhances Rhode Island’s and greater New England’s innovation ecosystem.”
A multi-year construction project is now underway to enhance 100 Technology Way’s existing capabilities as a cGMP facility. The building is fed by a significant utility infrastructure which will support Organogenesis’ manufacturing uses.
Organogenesis was represented by Robert Coughlin and Bobby Jangro of JLL. Mark Winters and Tyler McGrail of Newmark represented Davis and the property.
Davis Executes Full-building Lease Agreement with Oranogenesis at Premier Biomanufacturing Facility in Smithfield, RI
BOSTON, MA (May 15, 2025) –
The Davis Companies (Davis) today announced a full-building lease agreement at 100 Technology Way in Smithfield, RI, an approximately 123,000-square foot biomanufacturing facility, with Organogenesis Holdings Inc. (Organogenesis), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. Organogenesis will expand its biomanufacturing production lines to the site and will utilize its new space in Rhode Island to enhance the capabilities of its current production lines. The expansion highlights the commitment by Organogenesis to conduct its manufacturing operations in New England and continue to invest in the local economy.
“In a competitive manufacturing and life sciences market, our lease agreement with Organogenesis demonstrates Davis’ commitment to providing premier tenant experiences in locations that best allow businesses to innovate and scale,” said Davis’ Senior Vice President of Asset Management Jon Needham. “We are thrilled to welcome Organogenesis to the building and to support their growth plans as the company leads in the biomanufacturing sector and enhances Rhode Island’s and greater New England’s innovation ecosystem.”
A multi-year construction project is now underway which will enhance 100 Technology Way’s existing capabilities as a state-of-the-art cGMP facility. The building is fed by a significant utility infrastructure which will support Organogenesis’ manufacturing uses.
Situated just off Interstate 295 with more convenient access to Cambridge and Boston than is enjoyed by other biomanufacturing locations throughout greater Boston, 100 Technology Way is ideally situated to support biomanufacturing for New England’s life science community.
Organogenesis was represented by Robert Coughlin and Bobby Jangro of JLL, and Mark Winters and Tyler McGrail of Newmark represented Davis and the property.
Organogenesis Inks Full-Building Lease with Davis in RI
BOSTON, MA (May 19, 2025) The Davis Companies secured a full-building lease agreement at 100 Technology Way in Smithfield, RI, an approximately 123,000-square-foot biomanufacturing facility, with Organogenesis Holdings Inc., a leading regenerative medicine company. Lease terms were not disclosed.
“In a competitive manufacturing and life sciences market, our lease agreement with Organogenesis demonstrates Davis’ commitment to providing premier tenant experiences in locations that best allow businesses to innovate and scale,” said Davis SVP of asset management Jon Needham. “We are thrilled to welcome Organogenesis to the building and to support their growth plans as the company leads in the biomanufacturing sector and enhances Rhode Island’s and greater New England’s innovation ecosystem.”
A multi-year construction project is now underway to enhance 100 Technology Way’s existing capabilities as a cGMP facility. The building is fed by a significant utility infrastructure which will support Organogenesis’ manufacturing uses.
Organogenesis was represented by Robert Coughlin and Bobby Jangro of JLL. Mark Winters and Tyler McGrail of Newmark represented Davis and the property.
Davis Lands Full-Building Biomanufacturing Lease in Rhode Island
BOSTON, MA (May 13, 2025) –
Regenerative medicine company has signed a big biomanufacturing lease at a facility The Davis Cos. owns 50 miles south of Boston. The Boston-based developer landed a full-building, 123K SF lease with Organogenesis Holdings at its 100 Technology Way building in Smithfield, Rhode Island, Davis announced Thursday. “In a competitive manufacturing and life sciences market, our lease agreement with Organogenesis demonstrates Davis’ commitment to providing premier tenant experiences in locations that best allow businesses to innovate and scale,” Davis Senior Vice President of Asset Management Jon Needham said in a statement. Davis acquired the property in 2023 for $18.5M. It was previously occupied by Rubius Therapeutics, a cell and gene therapy manufacturer, and Alexion Pharmaceuticals before that.
The property also has 15.5 acres of vacant space approved for another 175K SF biomanufacturing building. Davis is undergoing a multiyear construction project that will “enhance 100 Technology Way’s existing capabilities.”
Davis Managing Director of Investment Sean Coffey said that although the building is in a smaller market outside of Boston, the area benefits from a strong workforce, particularly in biomanufacturing and life sciences.
“In addition, the state is very aggressive when it comes to putting incentive packages on the table to lure companies in to operate,” Coffey said at a Bisnow event last week. “I think it was a very nice surprise that we uncovered in our diligence process.”
JLL’s Robert Coughlin and Bobby Jangro represented the tenant, and Newmark’s Mark Winters and Tyler McGrail represented Davis.
Organogenesis is headquartered in Canton and has other offices and manufacturing facilities in San Diego, Birmingham, Alabama, and St. Petersburg, Florida. It also has international offices in Switzerland.
Closer to Boston, investors are making moves in the sector, including Bain Capital, which announced plans to develop a 154K SF biomanufacturing facility in Bedford last week. These moves come as big pharmaceutical companies like Pfizer, AstraZeneca and Eli Lilly have announced plans to invest billions in new biomanufacturing projects across the country.